Back to mobile site

More on BHVN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (6.8 Score)
- Holders
- Event Driven Deals

Upcoming Events

- Earnings (8/3/26)
- M&A (3/31/23 *Est)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Biohaven Pharma (NY:BHVN)
Delayed: 14.78 -0.72 (4.65%)
Prev. Close $15.50  
Open$15.04 
52 Wk High$ 
52 Wk Low$ 
Day High$15.80 
Day Low$14.75 
P/E N/A  
EPS$ 
Volume2,482,911 

Friends, Peers and Foes (?): QURE, REGN, ALNY, BEAM, BMRN (more...)

Jun 17, 2026 10:15 AM Increasing unusual option volume: BHVN DOMO CLPT OIH CVLT PEGA OTLK VT
Jun 1, 2026 07:31 AM Biohaven begins first human trial of brain-penetrant drug BHV-8100
Jun 1, 2026 07:30 AM Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
May 27, 2026 05:15 PM Form 8-K Biohaven Ltd. For: May 26
May 27, 2026 10:16 AM Raymond James on Biohaven Pharma (BHVN) with shares up 7%: 'Promising Degrader Data Sets Ahead of R&D Day'
May 27, 2026 07:31 AM Biohaven reports positive patient data for autoimmune disease drugs
May 27, 2026 07:30 AM Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Dise
May 26, 2026 07:31 AM Biohaven shares clinical data on epilepsy drug opakalim
May 26, 2026 07:30 AM Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
May 15, 2026 12:37 PM Form SCHEDULE 13G/A Biohaven Ltd. Filed by: JANUS HENDERSON GROUP PLC
View All Articles

Entities mentioned with BHVN

View All Entities